Nuvectra (NVTR) 10-Q 10 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jul. 01, 2016	Aug. 02, 2016
Document Information [Line Items]
Entity Registrant Name	Nuvectra Corp
Entity Central Index Key	1,648,893
Trading Symbol	nvtr
Current Fiscal Year End Date	--12-30
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		10,277,629
Document Type	10-Q
Document Period End Date	Jul. 1, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jul. 01, 2016	Jan. 01, 2016
Current assets:
Cash and cash equivalents	$ 83,525	$ 202
Trade accounts receivable, net of allowance for doubtful accounts of $37 in 2016 and $56 in 2015	2,024	417
Prepaid expenses and other current assets	1,589	145
Total current assets	87,138	764
Property, plant and equipment, net	5,493	4,469
Intangible assets, net	1,848	1,983
Goodwill	38,182	38,182
Other long-term assets	526
Total assets	133,187	45,398
Current liabilities:
Accounts payable and other current liabilities	5,813	18
Amount due to non-controlling interests		6,818
Deferred revenue	1,418
Other accrued compensation	1,052	524
Accrued bonuses	1,029	198
Total current liabilities	9,312	7,558
Other long-term liabilities	657
Long-term debt, net	13,422
Total liabilities	23,391	7,558
Stockholders’ equity:
Common stock, $0.001 par value, 100,000,000 shares authorized; 10,268,912 and 0 shares issued and outstanding in 2016 and 2015, respectively	10
Additional paid-in capital	120,497
Retained deficit	(10,711)	(125,094)
Greatbatch’s net investment		162,934
Total stockholders’ equity	109,796	37,840
Total liabilities and stockholders’ equity	$ 133,187	$ 45,398

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Jul. 01, 2016	Jan. 01, 2016
Trade accounts receivable, allowance for doubtful accounts	$ 37	$ 56
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	10,268,912	0
Common stock, shares outstanding (in shares)	10,268,912	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Product	$ 1,890	$ 1,497	$ 3,441	$ 2,671
Service	664		1,175
Total sales	2,554	1,497	4,616	2,671
Product	927	931	1,728	1,937
Service	336		590
Total cost of sales	1,263	931	2,318	1,937
Gross profit	1,291	566	2,298	734
Operating expenses:
Selling, general and administrative expenses	6,094	2,058	10,179	4,276
Research, development and engineering costs, net	3,447	4,652	6,983	7,691
Other operating expenses		34	469	458
Total operating expenses	9,541	6,744	17,631	12,425
Operating loss	(8,250)	(6,178)	(15,333)	(11,691)
Interest expense	464		523
Other expense	47		47
Loss before provision for income taxes	(8,761)	(6,178)	(15,903)	(11,691)
Provision for income taxes
Net loss	(8,761)	(6,178)	(15,903)	(11,691)
Comprehensive loss	$ (8,761)	$ (6,178)	$ (15,903)	$ (11,691)
Basic and diluted net loss per share (in dollars per share)	$ (0.85)	$ (0.60)	$ (1.55)	$ (1.14)
Basic and diluted weighted average shares outstanding (in shares)	10,266	10,258	10,262	10,258

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jul. 01, 2016	Jul. 03, 2015
Cash flows from operating activities:
Net loss	$ (15,903)	$ (11,691)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	938	298
Debt related amortization included in interest expense	188
Stock-based compensation	1,251	435
Loss on disposal of property, plant and equipment	21
Other non-cash losses, net		235
Changes in operating assets and liabilities:
Accounts receivable	(1,607)	150
Prepaid expenses and other current assets	(1,444)	177
Other long-term assets	(526)
Accounts payable and other current liabilities	7,602	(242)
Accrued bonuses	831	(263)
Other long-term liabilities	657
Net cash used in operating activities	(7,992)	(10,901)
Cash flows from investing activities:
Acquisition of property, plant and equipment	(1,819)	(363)
Net cash used in investing activities	(1,819)	(363)
Cash flows from financing activities:
Borrowings under credit facility	15,000
Purchase of non-controlling interests	(6,818)
Net funding and capital contribution provided by Greatbatch	86,421	12,520
Proceeds from the exercise of stock options	59
Payment of debt issuance costs	(1,528)
Net cash provided by financing activities	93,134	12,520
Net increase in cash and cash equivalents	83,323	1,256
Cash and cash equivalents, beginning of period	202	418
Cash and cash equivalents, end of period	$ 83,525	$ 1,674

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) $ in Thousands	6 Months Ended
	Jul. 01, 2016USD ($)
Property, plant, and equipment, additions	$ 1,900
Property, plant, and equipment, accrued costs	100
Payments to acquire property, plant, and equipment	$ 1,819

Condensed Consolidated Stateme7

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - 6 months ended Jul. 01, 2016 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Parent [Member]	Total
Balance (in shares) at Jan. 01, 2016	0
Balance at Jan. 01, 2016			$ (125,094)	$ 162,934	$ 37,840
Issuance of common stock (in shares)	10,258,000
Issuance of common stock	$ 10	$ 119,624	125,094	(244,728)
Issuance of common stock warrants		238			238
Option exercises (in shares)	11,000
Option exercises		59			59
Stock-based compensation		576		675	1,251
Capital contribution from Greatbatch				75,000	75,000
Net funding provided by Greatbatch				11,311	11,311
Net loss			(10,711)	(5,192)	(15,903)
Balance (in shares) at Jul. 01, 2016	10,269,000
Balance at Jul. 01, 2016	$ 10	$ 120,497	$ (10,711)		$ 109,796

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Background Nature of Operations Basis of Presentation Interim Reporting QiG historically operated as part of Greatbatch and not as a separate stand-alone entity. Prior to March 14, 2016, the financial statements of QiG were prepared on a “combined” basis from the consolidated financial statements of Greatbatch to represent the financial These Combined Financial Statements included an allocation of expenses related to certain Greatbatch corporate functions, including executive Greatbatch maintains a number of employee benefit and stock-based compensation programs at a corporate level. Nuvectra’s employees historically Greatbatch’s Net Investment in these Financial Statements represented the excess of total assets over total liabilities prior to the Spin-off. Greatbatch’s Net Investment was primarily impacted by contributions from Greatbatch and net funding of Nuvectra’s expenses provided by Greatbatch. Greatbatch paid for substantially all transaction costs, other than deferred financing fees for the credit facility, associated with the Spin-off. The Company has incurred significant net losses and negative cash flows from operations since inception and expects to incur additional net losses for the foreseeable future. Immediately prior to completion of the Spin-off, Greatbatch made a cash capital contribution to Nuvectra of $75 million. This cash capital contribution, together with the Company’s cash on hand and borrowings under the credit facility, $25 million of which is subject to achieving trailing six month revenue milestones and compliance with specified conditions and covenants , is an amount that the Company estimates will, based on its current plans and expectations, meet its cash needs for approximately two years after the completion of the Spin-off. The Company periodically evaluates its liquidity requirements, alternative uses of capital, capital needs and available resources. As a result of this process, the Company has in the past sought, and may in the future seek, to explore strategic alternatives to finance its business plan, including but not limited to, a public offering of its common stock, private equity or debt financings, or other sources, such as strategic partnerships. The Company is also focusing on increasing the sales of its products to generate cash flow to fund its operations. However, t here can be no assurance that the Company will be successful in its plans described above or in attracting alternative debt or equity financing. Fiscal Year End Impairment of Long-Lived Assets Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives of assets are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives. Goodwill is not amortized but is periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the Company’s reporting unit to its carrying value. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of its reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of its reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, the fair value for the Company’s reporting unit is determined based on discounted cash flows and market multiples. The Company completed its annual goodwill impairment assessment for fiscal year 2015 by performing a step zero qualitative analysis. As part of this analysis, the Company evaluated factors including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, the status of the development of its medical device initiatives, the status of regulatory approvals, the competitive environment, results of the last impairment test, and the operational stability and the overall financial performance of its reporting unit. After completing the analysis, the Company determined that it was more likely than not that its reporting unit’s fair value was greater than the reporting unit’s carrying value and the two-step impairment test was not necessary. Warranty Reserve , for any potential claims. The Company estimates its warranty reserve based upon an analysis of all identified or expected claims and an estimate of the cost to resolve those claims. Factors that affect the Company’s warranty liability include the number of units sold, historical and anticipated rates of warranty claims, and differences between actual and expected warranty costs per claim. The Company periodically assesses the adequacy of its warranty liabilities and adjusts the amounts as necessary. Revenue Recognition Service revenue is recognized as the services are performed. The Company’s development services are typically provided on a fixed-fee basis. The revenues for such longer duration projects are typically recognized using the proportional performance method. In using the proportional performance method, revenues are generally recorded based on the percentage of effort incurred to date on a contract relative to the estimated total expected contract effort. Significant judgment is required when estimating total contract effort and progress to completion on the arrangements as well as whether a loss is expected to be incurred on the contract. Management uses historical experience, project plans and an assessment of the risks and uncertainties inherent in the arrangements to establish these estimates. Various uncertainties may or may not be within the Company’s control. Deferred revenue consists primarily of service revenue not yet performed.

Note 2 - Intangible Assets

Note 2 - Intangible Assets	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	2. INTANGIBLE ASSETS Intangible assets are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Net Carrying Amount At July 1, 2016 Technology and patents $ 1,058 $ (443 ) $ 615 Customer lists 1,869 (636 ) 1,233 Total intangible assets $ 2,927 $ (1,079 ) $ 1,848 At January 1, 2016 Technology and patents $ 1,058 $ (388 ) $ 670 Customer lists 1,869 (556 ) 1,313 Total intangible assets $ 2,927 $ (944 ) $ 1,983 Aggregate intangible asset amortization expense is classified as follows (in thousands): Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Cost of sales $ 27 $ 33 $ 55 $ 66 Selling, general and administrative expenses 40 39 80 78 Total intangible asset amortization expense $ 67 $ 72 $ 135 $ 144 Estimated future intangible asset amortization expense based on the current carrying value is as follows (in thousands): Estimated Amortization Expense Remainder of 2016 $ 134 2017 286 2018 298 2019 293 2020 209 Thereafter 628 Total estimated amortization expense $ 1,848

Note 3 - Employee Benefit Plans

Note 3 - Employee Benefit Plans	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	3. EMPLOYEE BENEFIT PLANS Nuvectra Corporation 2016 Equity Incentive Plan During the second quarter of 2016 the Compensation Committee granted equity awards aggregating 763,468 shares of common stock under the 2016 Equity Plan in the form of both restricted stock units and non-qualified stock options to its directors and certain officers and key employees. Stock-Based Compensation The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Stock options $ 185 $ 54 $ 248 $ 108 Restricted stock and restricted stock units 360 165 1,003 327 Total stock-based compensation expense $ 545 $ 219 $ 1,251 $ 435 Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Selling, general and administrative expense $ 453 $ 140 $ 619 $ 281 Research, development and engineering costs, net 92 79 163 154 Other operating expenses — — 469 — Total stock-based compensation expense $ 545 $ 219 $ 1,251 $ 435 The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model with weighted-average assumptions based on the grant date. The weighted average fair value and assumptions used to value options granted under the 2016 Equity Plan are as follows: Three and Six Months Ended July 3, 2016 Weighted average fair value $ 4.50 Risk-free interest rate 1.72 % Expected volatility 55 % Expected life (in years) 10 Expected dividend yield — % The following table summarizes the stock option activity: Number of Time-Vested Stock Options Weighted Average Exercise Price Outstanding at March 14, 2016 605,257 $ 6.09 Granted 354,627 7.23 Exercised (10,634 ) 5.57 Forfeited or expired (7,543 ) 9.45 Outstanding at July 1, 2016 941,707 $ 6.50 Exercisable at July 1, 2016 479,647 $ 5.16 The following table summarizes the restricted stock and restricted stock unit activity: Time-Vested Activity Weighted Average Fair Value Nonvested at March 14, 2016 172,115 $ 6.97 Granted 436,611 6.93 Vested (2,117 ) 7.16 Forfeited (8,973 ) 6.88 Nonvested at July 1, 2016 597,636 $ 6.94 Nuvectra 2016 Bonus Plan Algovita Bonus Plan

Note 4 - Other Operating Expens

Note 4 - Other Operating Expenses	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
Other Operating Income and Expense [Text Block]	4. OTHER OPERATING EXPENSES Other Operating Expenses is comprised of the following (in thousands): Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Performance restricted stock expense $ — $ — $ 469 $ — Cleveland facility shutdown — 34 — 426 Other expenses — — — 32 Total other operating expense $ — $ 34 $ 469 $ 458 Performance Restricted Stock Expense Cleveland Facility Shutdown ● Severance and retention: $0.4 million; ● Asset write-offs: $0.3 million; ● Other: $0.4 million Other costs primarily consist of costs to relocate certain equipment and personnel and the related travel expenditures. All expenses are cash expenditures, except asset write-offs. Other Expenses

Note 5 - Debt

Note 5 - Debt	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	5. DEBT Long-term debt is comprised of the following (in thousands): As of July 1, 2016 January 1, 2016 Term loan $ 16,163 $ — Deferred financing fees (1,430 ) — Discount on debt (1,311 ) — Total long-term debt $ 13,422 $ — Credit Facility The Term Loans bear interest at a floating rate equal to the prime rate plus 4.15%, with a floor of 7.65%. At July 1, 2016 the interest rate on borrowings under the term loan was 7.65%. The Company pays monthly accrued interest only on the Term Loans through September 2017 (or March 2018 if the Term Loan B Commitment is funded), and thereafter the Company will pay monthly accrued interest on the Term Loans plus equal payments of principal for 36 months (or 30 months if the Term Loan B Commitment is funded). At the maturity of the Term Loans, on September 1, 2020, all principal on the Term Loans then outstanding, plus an additional 7.75% of the funded loan amounts (the “Final Payment”), will be due and payable. This Final Payment has been treated as an in substance discount and will be amortized using the effective interest method over the life of the loan. The Revolving Loans bear interest at a floating rate equal to the prime rate plus 3.45%, with a floor of 6.95%. The Company pays monthly accrued interest only on the Revolving Loans until maturity on March 18, 2018, at which time all principal on the Revolving Loans will be due and payable. There were no borrowings on the Revolving Loans as of July 1, 2016. The Company paid an arrangement fee of $1.1 million, a commitment fee of $200,000 for all of the Term Loan A, B, and C Commitments, and one-half of a $25,000 commitment fee for the Revolving Loans, with the remaining one-half due and payable on the one year anniversary of the initial closing. The Term Loan B Commitment and the Term Loan C Commitment are subject to a non-use fee of 2% of the amount of such commitment if the commitment becomes available, but the Company declines to borrow the Term Loans thereunder. If any Term Loans are voluntarily prepaid prior to their scheduled maturity, the Company must pay, in addition to the Final Payment, a prepayment fee equal to 3% of the prepaid principal if paid in the first year after the initial closing, 2% of the prepaid principal if paid in the second year after the initial closing, and 1% of the prepaid principal if paid thereafter. The Loans are secured by a first priority lien on substantially all of the assets of the Company, including, without limitation, all cash, deposit accounts, accounts receivable, equipment, inventory, contract rights, and the Company’s real property located in Blaine, Minnesota, but excluding all intellectual property of the Company (other than accounts receivable and proceeds of intellectual property). The Company’s intellectual property is subject to a negative pledge. The Company must maintain its primary operating and investment accounts with Silicon Valley Bank, which accounts are subject to customary control agreements. The Credit Facility contains customary representations and warranties, reporting and other covenants for credit facilities of this kind including prohibitions on the payment of cash dividends on the Company’s capital stock and restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates . If the lenders fund the Term Loan B Commitment, the Company will be subject to a quarterly financial covenant requiring the Company to achieve consolidated revenues of at least 75% of Nuvectra’s forecasts that have been previously approved by the lenders. The events of default in the Credit Facility are customary for credit facilities of this kind, and include failure to pay interest or principal, breaches of affirmative and negative covenants, a material adverse change occurring, and cross defaults to other material agreements of the Company. As a condition to the lenders’ funding the Loans under the Credit Facility, concurrently with the funding under the Term Loan A Commitment on March 18, 2016, (i) the Company issued to Oxford Finance LLC a warrant to purchase 56,533 shares of Nuvectra common stock at an exercise price of $5.97 per share, which warrant is exercisable until March 18, 2026 (the “Oxford Warrant”), and (ii) the Company issued to Silicon Valley Bank a warrant to purchase 56,533 shares of Nuvectra common stock at an exercise price of $5.97 per share, which warrant is exercisable until March 18, 2026 (the “Silicon Valley Warrant”). The fair value of the warrants on the date of grant totaled approximately $0.2 million and was recorded as a discount on long-term debt and as additional paid-in capital in the Condensed Consolidated Balance Sheets, as the warrants met the criteria under the relevant accounting standard for treatment as an equity instrument. The debt discount will be amortized over the term of the Term Loan A Commitment. Upon the funding of each of the Term Loan B Commitment and the Term Loan C Commitment, as applicable, Oxford Finance LLC and Silicon Valley Bank will each be entitled to additional warrants for the purchase of Nuvectra common stock. The number of shares under each warrant will be equal to the amount of the Term Loan made by each lender multiplied by 4.50% and divided by the then current trading price of Nuvectra common shares. The exercise price of the warrants will be equal to the trading price of Nuvectra common shares on the date of funding. The fair value of these future warrants as of July 1, 2016 was approximately $0.6 million and is recorded in other long-term liabilities in the Condensed Consolidated Balance Sheet. As of April 1, 2016, these warrants were classified as a derivative liability because the Company did not meet the criteria under the relevant accounting standard for treatment as equity instruments. As a result, the derivative liability warrants will be remeasured to its fair value at the end of each reporting period until it meets the requirements for equity treatment or is cancelled. Deferred Financing Fees – At January 1, 2016 $ — Additions during the period 1,528 Amortization during the period (98 ) At July 1, 2016 $ 1,430 In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs,” the Company has presented debt issuance costs as a direct deduction from Long-Term Debt in the Condensed Consolidated Balance Sheet.

Note 6 - Income Taxes

Note 6 - Income Taxes	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	6. INCOME TAXES The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws, business reorganizations and settlements with taxing authorities. The Company records a valuation allowance when it is “more likely than not” that all or a portion of a deferred tax asset will not be realized. Management reviews all available positive and negative evidence, including the Company’s current and past performance, the market environment in which the Company operates, the utilization of past tax credits, length of carry back and carry forward periods, existing contracts or sales backlog that will result in future profits, as well as other factors. The Company maintains a full valuation allowance on all of the net deferred tax assets for the periods presented. Until an appropriate level of profitability is sustained, the Company expects to continue to record a full valuation allowance on future tax benefits. Pursuant to the terms of the tax matters agreement with Greatbatch, for a period of two years following the date of the Spin-off, the Company will be prohibited from (i) causing or permitting to occur any transaction or series of transactions, subject to certain exceptions provided under the U.S. federal income tax rules, in connection with which one or more persons would (directly or indirectly) acquire an interest in its capital stock that, when combined with any other acquisition of an interest in its capital stock that occurs after the Spin-off, comprises 30% or more of the value or the total combined voting power of all interests that are treated as outstanding equity of Nuvectra for U.S. federal income tax purposes immediately after such transaction or, in the case of a series of related transactions, immediately after any transaction in such series; (ii) transferring, selling or otherwise disposing of 35% or more of its gross assets if such transfer, sale or other disposition would violate the IRS’ rules and regulations; (iii) liquidating its business or (iv) ceasing to maintain its active business. If the Company takes any of these actions and such actions result in tax-related costs for Greatbatch, then the Company would generally be required to indemnify Greatbatch for such costs. If the Company is unable to raise or are prohibited under the terms of the tax matters agreement with Greatbatch from raising additional funds when needed, it may be required to delay, reduce, or terminate some or all of its development plans.

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. COMMITMENTS AND CONTINGENCIES Litigation – Purchase Commitments

Note 8 - Earnings Per Share ("E

Note 8 - Earnings Per Share ("EPS")	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
Earnings Per Share [Text Block]	8. EARNINGS PER SHARE (“EPS”) Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is equal to basic net loss per share as the Company had no potentially dilutive securities outstanding for any of the periods presented. Prior to the Spin-off, the Company operated as part of Greatbatch and not as a separate entity. As a result, the Company did not have any common shares outstanding prior to March 14, 2016. The calculation of basic and diluted net loss per share assumes that the 10,258,278 shares issued to Greatbatch shareholders in connection with the Spin-off have been outstanding for all prior periods presented. The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts): Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3 , 2015 Basic net loss per share: Net loss $ (8,761 ) $ (6,178 ) $ (15,903 ) $ (11,691 ) Weighted average common shares outstanding 10,266 10,258 10,262 10,258 Basic net loss per share $ (0.85 ) $ (0.60 ) $ (1.55 ) $ (1.14 ) Diluted net loss per share: Net loss $ (8,761 ) $ (6,178 ) $ (15,903 ) $ (11,691 ) Weighted average common shares outstanding 10,266 10,258 10,262 10,258 Dilutive stock options, restricted stock and restricted stock units — — — — Weighted average common shares outstanding – assuming dilution 10,266 10,258 10,262 10,258 Diluted net loss per share $ (0.85 ) $ (0.60 ) $ (1.55 ) $ (1.14 ) Outstanding securities and warrants that were not included in the diluted calculation because their effect would be anti-dilutive 1,652 1,652 1,652 1,652

Note 9 - Fair Value Measurement

Note 9 - Fair Value Measurements	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	9. FAIR VALUE MEASUREMENTS The carrying amounts of cash, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items. As of July 1, 2016, the fair value of the Company’s variable rate long-term debt approximates its carrying value and is categorized in Level 2 of the fair value hierarchy. Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). The Company has categorized its warrants measured at fair value on a recurring basis in Level 3 of the fair value hierarchy. The fair value of the warrants classified as liability awards was determined by utilizing a Monte Carlo simulation model, which projects the value of Nuvectra stock versus its peer group under numerous scenarios, and determines the value of the award based upon the present value of these projected outcomes. The estimated fair value of the warrants as of the date of issuance was approximately $0.5 million, which has been recorded as a liability in the Condensed Consolidated Balance Sheet. The estimated fair value of the warrant liability will be revalued on a quarterly basis and any resulting increases or decreases in the estimated fair value will be recorded as an adjustment to operating earnings. For the three and six months ended July 1, 2016, the Company recorded approximately $0.1 million in fair value adjustments. The estimated fair value of the warrants as of July 1, 2016 was approximately $0.6 million. Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows: Long-lived Assets Goodwill Warrants The following table summarizes the assumptions used for estimating the fair value of the warrants: Risk-free interest rate 1.88 % Expected volatility 45.00 % Expected term (in years) 10 Dividend yield — %

Note 10 - Business Segment, Geo

Note 10 - Business Segment, Geographic and Concentration Risk Information	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
Segment Reporting, Geographical, and Concentration Risk Disclosure [Text Block]	10. BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION The Company operates as one reportable segment. Nuvectra’s revenue includes sales of neural interface technology, components and systems to the neuroscience and clinical markets, development and engineering service fees and sales from the limited release of Algovita in the United States and Europe. Future revenues of Nuvectra are expected to come primarily from sales of Algovita, particularly after expansion of its launch commercially in the United States, technology licensing fees, development service fees, and royalty fees. Product line sales for the Company were as follows (in thousands): Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Neural interface components and systems $ 1,321 $ 1,032 $ 2,457 $ 1,754 Development and engineering service 664 — 1,175 — Algovita 569 465 984 917 Total sales $ 2,554 $ 1,497 $ 4,616 $ 2,671 Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped or services are rendered (in thousands): Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Sales by geographic area: United States $ 1,163 $ 495 $ 1,827 $ 821 Non-Domestic locations: Germany 309 555 865 1,062 Rest of world 1,082 447 1,924 788 Total sales $ 2,554 $ 1,497 $ 4,616 $ 2,671 All of the Company’s long-lived tangible assets are located in the United States. The Company is dependent on Greatbatch to manufacture Algovita and its components. An inability to obtain a sufficient quantity of Algovita or its components could have a material adverse impact on the Company’s business, financial condition, and results of operations. See Note 11 “Related Party Transactions” for additional information regarding the Company’s relationship with Greatbatch.

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11. related party transactions Corporate Overhead Allocations from Greatbatch Corporate overhead allocations from Greatbatch were classified as follows (in thousands): Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Selling, general and administrative expenses $ — $ 252 $ 236 $ 517 Research, development and engineering costs, net — 445 — 890 Total $ — $ 697 $ 236 $ 1,407 The Company entered into, or amended, various agreements with Greatbatch to effect the Spin-off and to provide a framework for the Company’s relationship with Greatbatch going forward after the Spin-off including a supply agreement, license agreements, a separation and distribution agreement, a tax matters agreement, a transition services agreement and an employee matters agreement, which provided for the allocation between Nuvectra and Greatbatch of assets, employees, liabilities and obligations (including PP&E, employee benefits, and tax-related assets and liabilities) attributable to the Company’s business for the period prior to, at, and after the Spin-off. Immediately prior to the completion of the Spin-off, Greatbatch made a cash capital contribution to Nuvectra of $75.0 million. This cash capital contribution, together with the Company’s cash on hand and borrowings under the Credit Facility, $25 million of which is subject to achieving trailing six month revenue milestones and compliance with specified conditions and covenants , is an amount that the Company estimates will, based on its current plans and expectations, meet its cash needs for approximately two years after the completion of the Spin-off. The Company periodically evaluates its liquidity requirements, alternative uses of capital, capital needs and available resources. As a result of this process, the Company has in the past sought, and may in the future seek, to explore strategic alternatives to finance its business plan, including but not limited to, a public offering of its common stock, private equity or debt financings, or other sources, such as strategic partnerships. The Company is also focusing on increasing the sales of its products to generate cash flow to fund its operations. However, t here can be no assurance that the Company will be successful in its plans described above or in attracting alternative debt or equity financing. Employee Benefit Plans Insurance Supply Agreement Purchase of Non-controlling Interests

Note 12 - Recently Issued Accou

Note 12 - Recently Issued Accounting Standards	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	12. RECENTLY ISSUED ACCOUNTING STANDARDS In the normal course of business, management evaluates all new accounting pronouncements issued by the FASB, Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), and other authoritative accounting bodies to determine the potential impact they may have on the Company’s Condensed Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Condensed Consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting,” which amends Accounting Standards Codification ("ASC") Topic 718, Compensation – Stock Compensation. ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of the ASU on its Condensed Consolidated Financial Statements. In February 2016, the FASB issued ASU 2016-02, “Leases” in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. ASU 2016-02 requires that a lessee should recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of the ASU on its Condensed Consolidated Financial Statements. In January 2016, the FASB issued ASU No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities ,” which updates certain aspects of recognition, measurement, presentation and disclosure of financial instruments. The standard is effective for interim and annual periods beginning after December 31, 2017, and early adoption is not permitted. The Company is currently in the process of evaluating the impact of adoption of the ASU on its Condensed Consolidated Financial Statements. In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. This ASU is effective for annual periods ending after December 15, 2016, with early adoption permitted. The Company does not expect its pending adoption of ASU 2014-15 to have a material impact on its Condensed Consolidated Financial Statements. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” The core principle behind ASU 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. This model involves a five-step process that includes identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract, and recognizing revenue when the entity satisfies the performance obligations. This ASU allows two methods of adoption; a full retrospective approach where historical financial information is presented in accordance with the new standard, and a modified retrospective approach where this ASU is applied to the most current period presented in the financial statements. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers: Deferral of the Effective Date,” which deferred the effective date of ASU 2014-09 to annual reporting periods beginning after December 15, 2017, with earlier application permitted as of annual reporting periods beginning after December 15, 2016. In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” which clarified the revenue recognition implementation guidance on principal versus agent considerations and is effective during the same period as ASU 2014-09. In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” which clarified the revenue recognition guidance regarding the identification of performance obligations and the licensing implementation and is effective during the same period as ASU 2014-9. In May 2016, the FASB issued ASU 2016-11, “Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting .” The purpose of ASU 2016-11 is to rescind from the FASB Accounting Standards Codification certain SEC paragraphs as a result of two SEC Staff Announcements at the March 3, 2016 meeting. For public entities, the amendments in ASU 2016-11 related to Topic 605 are effective for interim and annual reporting periods beginning after December 15, 2017 and amendments related to Topic 815 are effective for interim and annual reporting periods beginning after December 15, 2015. In May 2016, the FASB also issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients,” which narrowly amended the revenue recognition guidance regarding collectability, noncash consideration, presentation of sales tax and transition and is effective during the same period as ASU 2014-9. The Company is currently assessing the financial impact of adopting these ASUs and the methods of adoption. Given the scope of the new standard, the Company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected.

Note 13 - Subsequent Events

Note 13 - Subsequent Events	6 Months Ended
	Jul. 01, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	13. subsequent events The Company evaluated subsequent events for recognition or disclosure through August 10, 2016, the date the Condensed Consolidated Financial Statements were available to be issued.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jul. 01, 2016
Accounting Policies [Abstract]
Nature of Operations [Policy Text Block]	Nature of Operations
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation Interim Reporting QiG historically operated as part of Greatbatch and not as a separate stand-alone entity. Prior to March 14, 2016, the financial statements of QiG were prepared on a “combined” basis from the consolidated financial statements of Greatbatch to represent the financial These Combined Financial Statements included an allocation of expenses related to certain Greatbatch corporate functions, including executive Greatbatch maintains a number of employee benefit and stock-based compensation programs at a corporate level. Nuvectra’s employees historically Greatbatch’s Net Investment in these Financial Statements represented the excess of total assets over total liabilities prior to the Spin-off. Greatbatch’s Net Investment was primarily impacted by contributions from Greatbatch and net funding of Nuvectra’s expenses provided by Greatbatch. Greatbatch paid for substantially all transaction costs, other than deferred financing fees for the credit facility, associated with the Spin-off. The Company has incurred significant net losses and negative cash flows from operations since inception and expects to incur additional net losses for the foreseeable future. Immediately prior to completion of the Spin-off, Greatbatch made a cash capital contribution to Nuvectra of $75 million. This cash capital contribution, together with the Company’s cash on hand and borrowings under the credit facility, $25 million of which is subject to achieving trailing six month revenue milestones and compliance with specified conditions and covenants , is an amount that the Company estimates will, based on its current plans and expectations, meet its cash needs for approximately two years after the completion of the Spin-off. The Company periodically evaluates its liquidity requirements, alternative uses of capital, capital needs and available resources. As a result of this process, the Company has in the past sought, and may in the future seek, to explore strategic alternatives to finance its business plan, including but not limited to, a public offering of its common stock, private equity or debt financings, or other sources, such as strategic partnerships. The Company is also focusing on increasing the sales of its products to generate cash flow to fund its operations. However, t here can be no assurance that the Company will be successful in its plans described above or in attracting alternative debt or equity financing.
Fiscal Period, Policy [Policy Text Block]	Fiscal Year End
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives of assets are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives. Goodwill is not amortized but is periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the Company’s reporting unit to its carrying value. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of its reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of its reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, the fair value for the Company’s reporting unit is determined based on discounted cash flows and market multiples. The Company completed its annual goodwill impairment assessment for fiscal year 2015 by performing a step zero qualitative analysis. As part of this analysis, the Company evaluated factors including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, the status of the development of its medical device initiatives, the status of regulatory approvals, the competitive environment, results of the last impairment test, and the operational stability and the overall financial performance of its reporting unit. After completing the analysis, the Company determined that it was more likely than not that its reporting unit’s fair value was greater than the reporting unit’s carrying value and the two-step impairment test was not necessary.
Standard Product Warranty, Policy [Policy Text Block]	Warranty Reserve , for any potential claims. The Company estimates its warranty reserve based upon an analysis of all identified or expected claims and an estimate of the cost to resolve those claims. Factors that affect the Company’s warranty liability include the number of units sold, historical and anticipated rates of warranty claims, and differences between actual and expected warranty costs per claim. The Company periodically assesses the adequacy of its warranty liabilities and adjusts the amounts as necessary.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Service revenue is recognized as the services are performed. The Company’s development services are typically provided on a fixed-fee basis. The revenues for such longer duration projects are typically recognized using the proportional performance method. In using the proportional performance method, revenues are generally recorded based on the percentage of effort incurred to date on a contract relative to the estimated total expected contract effort. Significant judgment is required when estimating total contract effort and progress to completion on the arrangements as well as whether a loss is expected to be incurred on the contract. Management uses historical experience, project plans and an assessment of the risks and uncertainties inherent in the arrangements to establish these estimates. Various uncertainties may or may not be within the Company’s control. Deferred revenue consists primarily of service revenue not yet performed.
New Accounting Pronouncements, Policy [Policy Text Block]	In the normal course of business, management evaluates all new accounting pronouncements issued by the FASB, Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), and other authoritative accounting bodies to determine the potential impact they may have on the Company’s Condensed Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Condensed Consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting,” which amends Accounting Standards Codification ("ASC") Topic 718, Compensation – Stock Compensation. ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of the ASU on its Condensed Consolidated Financial Statements. In February 2016, the FASB issued ASU 2016-02, “Leases” in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. ASU 2016-02 requires that a lessee should recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of the ASU on its Condensed Consolidated Financial Statements. In January 2016, the FASB issued ASU No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities ,” which updates certain aspects of recognition, measurement, presentation and disclosure of financial instruments. The standard is effective for interim and annual periods beginning after December 31, 2017, and early adoption is not permitted. The Company is currently in the process of evaluating the impact of adoption of the ASU on its Condensed Consolidated Financial Statements. In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. This ASU is effective for annual periods ending after December 15, 2016, with early adoption permitted. The Company does not expect its pending adoption of ASU 2014-15 to have a material impact on its Condensed Consolidated Financial Statements. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” The core principle behind ASU 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. This model involves a five-step process that includes identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract, and recognizing revenue when the entity satisfies the performance obligations. This ASU allows two methods of adoption; a full retrospective approach where historical financial information is presented in accordance with the new standard, and a modified retrospective approach where this ASU is applied to the most current period presented in the financial statements. In August 2015, the FASB issued ASU 2015-14 “Revenue from Contracts with Customers: Deferral of the Effective Date,” which deferred the effective date of ASU 2014-09 to annual reporting periods beginning after December 15, 2017, with earlier application permitted as of annual reporting periods beginning after December 15, 2016. In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” which clarified the revenue recognition implementation guidance on principal versus agent considerations and is effective during the same period as ASU 2014-09. In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” which clarified the revenue recognition guidance regarding the identification of performance obligations and the licensing implementation and is effective during the same period as ASU 2014-9. In May 2016, the FASB issued ASU 2016-11, “Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting .” The purpose of ASU 2016-11 is to rescind from the FASB Accounting Standards Codification certain SEC paragraphs as a result of two SEC Staff Announcements at the March 3, 2016 meeting. For public entities, the amendments in ASU 2016-11 related to Topic 605 are effective for interim and annual reporting periods beginning after December 15, 2017 and amendments related to Topic 815 are effective for interim and annual reporting periods beginning after December 15, 2015. In May 2016, the FASB also issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients,” which narrowly amended the revenue recognition guidance regarding collectability, noncash consideration, presentation of sales tax and transition and is effective during the same period as ASU 2014-9. The Company is currently assessing the financial impact of adopting these ASUs and the methods of adoption. Given the scope of the new standard, the Company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected.

Note 2 - Intangible Assets (Tab

Note 2 - Intangible Assets (Tables)	6 Months Ended
	Jul. 01, 2016
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Gross Carrying Amount Accumulated Amortization Net Carrying Amount At July 1, 2016 Technology and patents $ 1,058 $ (443 ) $ 615 Customer lists 1,869 (636 ) 1,233 Total intangible assets $ 2,927 $ (1,079 ) $ 1,848 At January 1, 2016 Technology and patents $ 1,058 $ (388 ) $ 670 Customer lists 1,869 (556 ) 1,313 Total intangible assets $ 2,927 $ (944 ) $ 1,983
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Cost of sales $ 27 $ 33 $ 55 $ 66 Selling, general and administrative expenses 40 39 80 78 Total intangible asset amortization expense $ 67 $ 72 $ 135 $ 144
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated Amortization Expense Remainder of 2016 $ 134 2017 286 2018 298 2019 293 2020 209 Thereafter 628 Total estimated amortization expense $ 1,848

Note 3 - Employee Benefit Pla23

Note 3 - Employee Benefit Plans (Tables)	6 Months Ended
	Jul. 01, 2016
Restricted Stock and RSU's [Member]
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Time-Vested Activity Weighted Average Fair Value Nonvested at March 14, 2016 172,115 $ 6.97 Granted 436,611 6.93 Vested (2,117 ) 7.16 Forfeited (8,973 ) 6.88 Nonvested at July 1, 2016 597,636 $ 6.94
Employee Stock Option [Member]
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Number of Time-Vested Stock Options Weighted Average Exercise Price Outstanding at March 14, 2016 605,257 $ 6.09 Granted 354,627 7.23 Exercised (10,634 ) 5.57 Forfeited or expired (7,543 ) 9.45 Outstanding at July 1, 2016 941,707 $ 6.50 Exercisable at July 1, 2016 479,647 $ 5.16
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Stock options $ 185 $ 54 $ 248 $ 108 Restricted stock and restricted stock units 360 165 1,003 327 Total stock-based compensation expense $ 545 $ 219 $ 1,251 $ 435 Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Selling, general and administrative expense $ 453 $ 140 $ 619 $ 281 Research, development and engineering costs, net 92 79 163 154 Other operating expenses — — 469 — Total stock-based compensation expense $ 545 $ 219 $ 1,251 $ 435
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three and Six Months Ended July 3, 2016 Weighted average fair value $ 4.50 Risk-free interest rate 1.72 % Expected volatility 55 % Expected life (in years) 10 Expected dividend yield — %

Note 4 - Other Operating Expe24

Note 4 - Other Operating Expenses (Tables)	6 Months Ended
	Jul. 01, 2016
Notes Tables
Schedule of Other Operating Cost and Expense, by Component [Table Text Block]	Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Performance restricted stock expense $ — $ — $ 469 $ — Cleveland facility shutdown — 34 — 426 Other expenses — — — 32 Total other operating expense $ — $ 34 $ 469 $ 458

Note 5 - Debt (Tables)

Note 5 - Debt (Tables)	6 Months Ended
	Jul. 01, 2016
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	As of July 1, 2016 January 1, 2016 Term loan $ 16,163 $ — Deferred financing fees (1,430 ) — Discount on debt (1,311 ) — Total long-term debt $ 13,422 $ —
Schedule of Debt Issuance Costs [Table Text Block]	At January 1, 2016 $ — Additions during the period 1,528 Amortization during the period (98 ) At July 1, 2016 $ 1,430

Note 8 - Earnings Per Share (26

Note 8 - Earnings Per Share ("EPS") (Tables)	6 Months Ended
	Jul. 01, 2016
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3 , 2015 Basic net loss per share: Net loss $ (8,761 ) $ (6,178 ) $ (15,903 ) $ (11,691 ) Weighted average common shares outstanding 10,266 10,258 10,262 10,258 Basic net loss per share $ (0.85 ) $ (0.60 ) $ (1.55 ) $ (1.14 ) Diluted net loss per share: Net loss $ (8,761 ) $ (6,178 ) $ (15,903 ) $ (11,691 ) Weighted average common shares outstanding 10,266 10,258 10,262 10,258 Dilutive stock options, restricted stock and restricted stock units — — — — Weighted average common shares outstanding – assuming dilution 10,266 10,258 10,262 10,258 Diluted net loss per share $ (0.85 ) $ (0.60 ) $ (1.55 ) $ (1.14 ) Outstanding securities and warrants that were not included in the diluted calculation because their effect would be anti-dilutive 1,652 1,652 1,652 1,652

Note 9 - Fair Value Measureme27

Note 9 - Fair Value Measurements (Tables)	6 Months Ended
	Jul. 01, 2016
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	Risk-free interest rate 1.88 % Expected volatility 45.00 % Expected term (in years) 10 Dividend yield — %

Note 10 - Business Segment, G28

Note 10 - Business Segment, Geographic and Concentration Risk Information (Tables)	6 Months Ended
	Jul. 01, 2016
Notes Tables
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Neural interface components and systems $ 1,321 $ 1,032 $ 2,457 $ 1,754 Development and engineering service 664 — 1,175 — Algovita 569 465 984 917 Total sales $ 2,554 $ 1,497 $ 4,616 $ 2,671
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Sales by geographic area: United States $ 1,163 $ 495 $ 1,827 $ 821 Non-Domestic locations: Germany 309 555 865 1,062 Rest of world 1,082 447 1,924 788 Total sales $ 2,554 $ 1,497 $ 4,616 $ 2,671

Note 11 - Related Party Trans29

Note 11 - Related Party Transactions (Tables)	6 Months Ended
	Jul. 01, 2016
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Three Months Ended Six Months Ended July 1, 2016 July 3, 2015 July 1, 2016 July 3, 2015 Selling, general and administrative expenses $ — $ 252 $ 236 $ 517 Research, development and engineering costs, net — 445 — 890 Total $ — $ 697 $ 236 $ 1,407

Note 1 - Summary of Significa30

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Mar. 14, 2016	Jul. 01, 2016	Jul. 03, 2015
Greatbatch [Member]
Proceeds from Contributions from Former Parent	$ 75,000
Period in Which Contribution from Parent Will Fund Operations	2 years
Proceeds from Contributions from Former Parent		$ 86,421	$ 12,520
Line of Credit, Portion Subject to Certain Revenue Milestones	$ 25,000

Note 2 - Amortizing Intangible

Note 2 - Amortizing Intangible Assets (Details) - USD ($) $ in Thousands	Jul. 01, 2016	Jan. 01, 2016
Patented Technology [Member]
Gross carrying amount	$ 1,058	$ 1,058
Accumulated amortization	(443)	(388)
Net carrying amount	615	670
Customer Lists [Member]
Gross carrying amount	1,869	1,869
Accumulated amortization	(636)	(556)
Net carrying amount	1,233	1,313
Gross carrying amount	2,927	2,927
Accumulated amortization	(1,079)	(944)
Net carrying amount	$ 1,848	$ 1,983

Note 2 - Aggregate Intangible A

Note 2 - Aggregate Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Cost of Sales [Member]
Intangible asset amortization expense	$ 27	$ 33	$ 55	$ 66
Selling, General and Administrative Expenses [Member]
Intangible asset amortization expense	40	39	80	78
Intangible asset amortization expense	$ 67	$ 72	$ 135	$ 144

Note 2 - Future Intangible Asse

Note 2 - Future Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	Jul. 01, 2016	Jan. 01, 2016
Remainder of 2016	$ 134
2,017	286
2,018	298
2,019	293
2,020	209
Thereafter	628
Total estimated amortization expense	$ 1,848	$ 1,983

Note 3 - Employee Benefit Pla34

Note 3 - Employee Benefit Plans (Details Textual) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Nuvectra Corporation 2016 Equity Incentive Plan [Member] | Restricted Stock Units and Non-Qualified Stock Options [Member] | Directors, Certain Officers and Key Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options and Options, Grants in Period	763,468
Nuvectra Corporation 2016 Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance	1,128,410		1,128,410
Bonus 2016 Plan [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense	$ 0.3		$ 1
Algovita Bonus Plan [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense		$ 0.5		$ 0.6

Note 3 - Allocated Stock-based

Note 3 - Allocated Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Employee Stock Option [Member]
Allocated share-based compensation expense	$ 185	$ 54	$ 248	$ 108
Restricted Stock Units (RSUs) [Member]
Allocated share-based compensation expense	360	165	1,003	327
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	453	140	619	281
Research and Development Expense [Member]
Allocated share-based compensation expense	92	79	163	154
Other Operating Income (Expense) [Member]
Allocated share-based compensation expense			469
Allocated share-based compensation expense	$ 545	$ 219	$ 1,251	$ 435

Note 3 - Weighted Average Fair

Note 3 - Weighted Average Fair Value Assumption Used to Values Options Granted (Details)	6 Months Ended
	Jul. 01, 2016$ / shares
Weighted average fair value (in dollars per share)	$ 4.50
Risk-free interest rate	1.72%
Expected volatility	55.00%
Expected life (in years)	10 years
Expected dividend yield	0.00%

Note 3 - Summary of Stock Optio

Note 3 - Summary of Stock Option Activity (Details) - Employee Stock Option [Member] - $ / shares	4 Months Ended
	Jul. 01, 2016	Mar. 14, 2016
Outstanding at March 14, 2016 (in shares)	941,707	605,257
Outstanding at March 14, 2016 (in dollars per share)	$ 6.50	$ 6.09
Granted (in shares)	354,627
Granted (in dollars per share)	$ 7.23
Exercised (in shares)	(10,634)
Exercised (in dollars per share)	$ 5.57
Forfeited or expired (in shares)	(7,543)
Forfeited or expired (in dollars per share)	$ 9.45
Exercisable at July 1, 2016 (in shares)	479,647
Exercisable at July 1, 2016 (in dollars per share)	$ 5.16

Note 3 - Summary Restricted Sto

Note 3 - Summary Restricted Stock Unit Activity (Details) - Restricted Stock and RSU's [Member] - $ / shares	4 Months Ended
	Jul. 01, 2016	Mar. 14, 2016
Nonvested at March 14, 2016 (in shares)	597,636	172,115
Nonvested at March 14, 2016 (in dollars per share)	$ 6.94	$ 6.97
Granted (in shares)	436,611
Granted (in dollars per share)	$ 6.93
Vested (in shares)	(2,117)
Vested (in dollars per share)	$ 7.16
Forfeited (in shares)	(8,973)
Forfeited (in dollars per share)	$ 6.88

Note 4 - Other Operating Expe39

Note 4 - Other Operating Expenses (Details Textual) - Cleveland Facility Shutdown [Member] $ in Millions	24 Months Ended
	Dec. 31, 2015USD ($)
Restructuring Charges	$ 1.1
Severance and Retention Costs	0.4
Asset Impairment Charges	0.3
Other Restructuring Costs	$ 0.4

Note 4 - Schedule of Other Oper

Note 4 - Schedule of Other Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jul. 03, 2016	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Performance Restricted Stock Expense [Member]
Other operating expenses				$ 469
Cleveland Facility Shutdown [Member]
Other operating expenses			34		426
Other Expenses [Member]
Other operating expenses					32
Other operating expenses			$ 34	$ 469	$ 458

Note 5 - Debt (Details Textual)

Note 5 - Debt (Details Textual) - USD ($)	Mar. 18, 2016	Jul. 01, 2016	Jan. 01, 2016
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		4.15%
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | If Term Loan B Not Funded, Beginning September, 2017 [Member]
Debt Instrument, Number of Monthly Principal and Interest Payments		36
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | If Term Loan B Funded, Beginning March, 2018 [Member]
Debt Instrument, Number of Monthly Principal and Interest Payments		30
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | Prepayment in First Year After Initial Closing [Member]
Debt Instrument, Prepayment Fee Percentage		3.00%
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | Prepayment in Second Year After Initial Closing [Member]
Debt Instrument, Prepayment Fee Percentage		2.00%
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | Prepayment After Second Year After Initial Closing [Member]
Debt Instrument, Prepayment Fee Percentage		1.00%
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member]
Debt Agreement, Maximum Borrowing Capacity		$ 40,000,000
Debt Instrument, Interest Rate Floor		7.65%
Debt Instrument, Interest Rate During Period		7.65%
Debt Instrument, Percentage of Funded Loan Amounts due at Maturity		7.75%
Debt Instrument, Commitment Fee Amount		$ 200,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loan A [Member]
Debt Agreement, Maximum Borrowing Capacity		15,000,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loan B [Member]
Debt Agreement, Maximum Borrowing Capacity		12,500,000
Debt Covenant, Minimum Revenue Required for Trailing Six Months		13,500,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loan C [Member]
Debt Agreement, Maximum Borrowing Capacity		12,500,000
Debt Covenant, Minimum Revenue Required for Trailing Six Months		$ 20,000,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans B and C [Member]
Debt Covenant, Maximum Number of Days to Draw Loan After Revenue Requirement		60 days
Debt Instrument, Commitment Fee Percentage		2.00%
Oxford Finance LLC and Silicon Valley Bank [Member] | Revolving Credit Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		3.45%
Oxford Finance LLC and Silicon Valley Bank [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 5,000,000
Line of Credit Facility, Borrowing Base as Percentage of Accounts Receivable		80.00%
Debt Instrument, Interest Rate Floor		6.95%
Line of Credit Facility, Commitment Fee Amount		$ 25,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | Piper Jaffray [Member]
Debt Instrument, Fee Amount		$ 1,100,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loan B Funded [Member]
Debt Covenant, Minimum Percentage of Forecasted Revenues Required		75.00%
Oxford Finance LLC and Silicon Valley Bank [Member] | Warrant [Member]
Additional Paid in Capital	$ 200,000
Oxford Finance LLC [Member]
Class of Warrant or Right, Issued During Period	56,533
Class of Warrant or Right, Issued During Period, Exercise Price	$ 5.97
Silicon Valley Bank [Member] | Term Loan B Funded [Member] | Warrant [Member]
Derivative Liability		$ 600,000
Silicon Valley Bank [Member] | Term Loan B Funded [Member]
Class of Warrant or Right, Increase to Warrant, Percentage of Loan Divided by Market Value of Common Stock	4.50%
Silicon Valley Bank [Member]
Class of Warrant or Right, Issued During Period	56,533
Class of Warrant or Right, Issued During Period, Exercise Price	$ 5.97
Warrant [Member]
Derivative Liability	$ 500,000	600,000
Additional Paid in Capital		$ 120,497,000

Note 5 - Long-term Debt (Detail

Note 5 - Long-term Debt (Details) - USD ($) $ in Thousands	Jul. 01, 2016	Jan. 01, 2016
Term loan	$ 16,163
Deferred financing fees	(1,430)
Discount on debt	(1,311)
Total long-term debt	$ 13,422

Note 5 - Deferred Financing Fee

Note 5 - Deferred Financing Fees (Details) $ in Thousands	6 Months Ended
	Jul. 01, 2016USD ($)
Deferred financing fees
Additions during the period	1,528
Amortization during the period	(98)
Deferred financing fees	$ 1,430

Note 6 - Income Taxes (Details

Note 6 - Income Taxes (Details Textual) - Greatbatch [Member]	Mar. 14, 2016	Jul. 01, 2016
Tax Matters Agreement [Member]
Equity Issuance Limitations		30.00%
Asset Disposal Limitations		35.00%
Tax Matters Agreement, Term	2 years

Note 7 - Commitments and Cont45

Note 7 - Commitments and Contingencies (Details Textual) $ in Millions	6 Months Ended
	Jul. 01, 2016USD ($)
Purchase Commitment, Remaining Minimum Amount Committed	$ 6.3
Capital Expenditures Yet to Be Incurred	$ 2.1

Note 8 - Earnings Per Share (46

Note 8 - Earnings Per Share ("EPS") (Details Textual) - shares	3 Months Ended		6 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015	Mar. 14, 2016	Mar. 13, 2016	Jan. 01, 2016
Weighted Average Number Diluted Shares Outstanding Adjustment	0	0	0	0
Common Stock, Shares, Outstanding	10,268,912		10,268,912		10,258,278	0	0

Note 8 - Basic and Diluted Earn

Note 8 - Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Warrant [Member]
Diluted net loss per share:
Outstanding securities and warrants that were not included in the diluted calculation because their effect would be anti-dilutive (in shares)	1,652	1,652	1,652	1,652
Net loss	$ (8,761)	$ (6,178)	$ (15,903)	$ (11,691)
Weighted average common shares outstanding (in shares)	10,266	10,258	10,262	10,258
Basic net loss per share (in dollars per share)	$ (0.85)	$ (0.60)	$ (1.55)	$ (1.14)
Net loss	$ (8,761)	$ (6,178)	$ (15,903)	$ (11,691)
Weighted average common shares outstanding (in shares)	10,266	10,258	10,262	10,258
Dilutive stock options, restricted stock and restricted stock units (in shares)
Weighted average common shares outstanding – assuming dilution (in shares)	10,266	10,258	10,262	10,258
Diluted net loss per share (in dollars per share)	$ (0.85)	$ (0.60)	$ (1.55)	$ (1.14)

Note 9 - Fair Value Measureme48

Note 9 - Fair Value Measurements (Details Textual) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jul. 01, 2016	Jul. 01, 2016	Mar. 18, 2016
Warrant [Member]
Derivative Liability	$ 0.6	$ 0.6	$ 0.5
Fair Value Adjustment of Warrants	$ 0.1	$ 0.1

Note 9 - Fair Value Assumptions

Note 9 - Fair Value Assumptions of Warrants (Details) - Warrant [Member]	6 Months Ended
	Jul. 01, 2016
Risk-free interest rate	1.88%
Expected volatility	45.00%
Expected term (in years)	10 years
Dividend yield	0.00%

Note 10 - Business Segment, G50

Note 10 - Business Segment, Geographic and Concentration Risk Information (Details Textual)	6 Months Ended
	Jul. 01, 2016
Number of Reportable Segments	1

Note 10 - Product Line Sales (D

Note 10 - Product Line Sales (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Neural Interface Components and Systems [Member]
Sales revenue, net	$ 1,321		$ 1,032	$ 2,457	$ 1,754
Development and Engineering Services [Member]
Sales revenue, net	664			1,175
Algovita [Member]
Sales revenue, net	569		465	984	917
Sales revenue, net	$ 2,554	$ 1,497	$ 1,497	$ 4,616	$ 2,671

Note 10 - Sales by Geographic A

Note 10 - Sales by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
UNITED STATES
Sales revenue, net	$ 1,163	$ 495		$ 1,827	$ 821
GERMANY
Sales revenue, net	309	555		865	1,062
Rest of World [Member]
Sales revenue, net	1,082	447		1,924	788
Sales revenue, net	$ 2,554	$ 1,497	$ 1,497	$ 4,616	$ 2,671

Note 11 - Related Party Trans53

Note 11 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	Mar. 14, 2016	Jan. 31, 2016	Dec. 31, 2015	Jan. 31, 2016	Jul. 01, 2016	Jul. 03, 2015
Greatbatch [Member]
Proceeds from Contributions from Parent	$ 75,000
Period in Which Contribution from Parent Will Fund Operations	2 years
Drees Holding LLC [Member]
Payments to Noncontrolling Interests				$ 6,900
Executive Vice President of Research and Development [Member]
Payments to Noncontrolling Interests				$ 848
Line of Credit, Portion Subject to Certain Revenue Milestones	$ 25,000
Noncontrolling Interest, Increase from Business Combination			$ 16,700
Payments to Noncontrolling Interests		$ 6,800	$ 9,900		$ 6,818

Note 11 - Corporate Overhead Al

Note 11 - Corporate Overhead Allocations (Details) - Greatbatch [Member] - Corporate Overhead Allocations [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Selling, General and Administrative Expenses [Member]
Expenses from transactions with related party		$ 252	$ 236	$ 517
Research and Development Expense [Member]
Expenses from transactions with related party		445		890
Expenses from transactions with related party		$ 697	$ 236	$ 1,407